JG
IBRX icon

Joel Greenblatt’s ImmunityBio IBRX Stock Holding History

Joel Greenblatt’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54M Buy
175,564
+163,427
+1,347% +$1.24M ﹤0.01% 1233
2026
Q1 		$93.1K Buy
+12,137
New +$83.1K ﹤0.01% 1725
2025
Q3 		– Sell
-16,224
Closed -$42.8K – 1749
2025
Q2 		$42.8K Sell
16,224
-28,781
-64% -$77.4K ﹤0.01% 1649
2025
Q1 		$135K Buy
+45,005
New +$136K ﹤0.01% 1494
2024
Q3 		– Sell
-14,594
Closed -$92.2K – 1471
2024
Q2 		$92.2K Sell
14,594
-17,932
-55% -$118K ﹤0.01% 1384
2024
Q1 		$175K Buy
32,526
+21,738
+202% +$98.4K ﹤0.01% 1299
2023
Q4 		$54.2K Buy
+10,788
New +$33.9K ﹤0.01% 1308
2020
Q3 		– Sell
-27,855
Closed -$342K – 1083
2020
Q2 		$342K Buy
+27,855
New +$157K 0.01% 834
2017
Q3 		– Sell
-13,766
Closed -$104K – 969
2017
Q2 		$104K Buy
+13,766
New +$59.5K ﹤0.01% 929

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Joel Greenblatt's IBRX Position: Q2 2026 in Review

Joel Greenblatt increased its ImmunityBio (IBRX) stake by 1,347% in Q2 2026, buying an estimated $1.24M and bringing the position to 175,564 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1233.

Joel Greenblatt first reported a position in IBRX in Q2 2017 and has held it in 9 quarters since. 402 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Joel Greenblatt held 175,564 shares of ImmunityBio worth $1.54M as of Q2 2026.
  • Joel Greenblatt bought 163,427 ImmunityBio shares in Q2 2026, an estimated $1.24M.
  • ImmunityBio made up ﹤0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1233 holding.
  • Joel Greenblatt first reported a position in ImmunityBio in Q2 2017 and has held it in 9 quarters since.
  • 402 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.